Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences
February 24, 2014 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences.
JMP...
Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial
February 20, 2014 07:00 ET
|
Raptor Pharmaceutical Inc
18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine
Conference Call and Webcast Today at 8:30 a.m. EST
NOVATO,...
Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
January 13, 2014 07:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103...
Raptor Submits IND for RP103 for Leigh Syndrome and Other Mitochondrial Disorders
December 10, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and...
Raptor Pharmaceutical Corp. Provides PROCYSBI(R) Launch Update and Third Quarter 2013 Financial Results
November 07, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided financial results for its third quarter and nine months ended September 30, 2013.
PROCYSBI...
Raptor Pharmaceuticals and DaVita Clinical Research Launch Screening Program to Identify Patients With Late Onset Nephropathic Cystinosis
October 23, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) and DaVita Clinical Research® (DCR®) (NYSE:DVA) today announced a collaboration to screen blood...
Raptor Pharmaceutical to Hold Third Quarter 2013 Financial Results Webcast and Conference Call
October 21, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release third quarter 2013 financial results after market close on Thursday,...
Raptor Pharmaceutical to Present at Leerink Swann Rare Disease Roundtable
September 26, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced management will present at the Leerink Swann Rare Disease Roundtable in New York on October...
Raptor Pharmaceutical Receives Marketing Authorization for PROCYSBI(R) in European Union
September 12, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the European Commission (EC) has approved PROCYSBI® gastro-resistant hard...
Raptor Pharmaceutical Announces Presentation at the International Pediatric Nephrology Association Meeting in Shanghai
August 29, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI (cysteamine bitartrate) will be featured in an upcoming presentation at the...